Related Experiment Video
Updated: May 4, 2026
04:37
Improved Home Blood Pressure Control by CT-guided Ozone-mediated Renal Denervation for Patients with Resistant Hypertension
Published on: June 6, 2025
847
Resistant hypertension optimal treatment trial: a randomized controlled trial
Clinical Cardiology
|December 17, 2013
Summary
This study investigates resistant hypertension (ReHy) prevalence and compares spironolactone versus clonidine as add-on therapies. Findings will guide optimal fourth-drug selection for better blood pressure control in ReHy patients.
Area of Science:
- Cardiology
- Clinical Trials
- Pharmacology
Background:
- Resistant hypertension (ReHy) prevalence is unclear.
- Standard 3-drug regimens for ReHy often require additional medication.
- The optimal fourth drug for ReHy remains controversial.
Purpose of the Study:
- Determine ReHy prevalence in stage II hypertension.
- Compare spironolactone versus clonidine as add-on therapy to a 3-drug regimen.
- Evaluate biomarkers for predicting treatment response.
Main Methods:
- Prospective, multicenter, randomized trial (ReHOT study).
- Step 1: Assess ReHy prevalence in 2000 patients over 12 weeks.
- Step 2: Randomize confirmed ReHy patients to spironolactone or clonidine for 3 months.
Main Results:
- Primary endpoint: blood pressure control after 12 weeks of randomized treatment.
- Adherence monitored by pill count.
- Results will inform ReHy management strategies.
Conclusions:
- The ReHOT study will establish ReHy prevalence in stage II hypertension.
- It will compare spironolactone and clonidine efficacy in ReHy.
- Findings aim to optimize treatment for patients with difficult-to-control hypertension.
Related Concept Videos
01:28Hypertension IV: Drug Therapy and Lifestyle Modifications
1.0K
Multiple classes of antihypertensive medications are employed in treating hypertension. The most commonly recommended first-line treatments include:Thiazide Diuretics, such as chlorthalidone, increase sodium and water excretion from the body, reducing blood volume and blood pressure.Angiotensin-converting enzyme inhibitors, like lisinopril, block the conversion of angiotensin I to II, a potent vasoconstrictor lowering blood pressure.Angiotensin II Receptor Blockers (ARBs) prevent angiotensin II...
1.0K
01:30Hypertension III: Clinical Manifestations and Diagnostic Studies
886
Hypertension is asymptomatic and also referred to as the "silent killer" until it progresses to a severe stage or causes target organ disease. Patients may experience symptoms stemming from the strain on blood vessels and tissues in various organs or the heart's increased workload.Physical exams might show no abnormalities other than high blood pressure. Signs of vascular damage, when present, correspond to the organs supplied by the affected vessels, leading to target organ damage. For...
886
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
1.9K
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
1.9K
01:23Hypertension V: Nursing Management
687
The nursing management of hypertension involves accurately assessing symptoms, making a comprehensive nursing diagnosis, collaborating with patients to set goals, and implementing targeted interventions to mitigate the condition's impact and improve patient well-being.Comprehensive AssessmentThe initial step in nursing care for hypertension involves a thorough patient assessment. It includes evaluating symptoms such as headaches, dizziness, blurred vision, and previous hypertension episodes.
687
01:26Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
689
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
689
01:18Hypertension and Regulation of Blood Pressure
3.8K
Hypertension, the most common cardiovascular disease, is diagnosed through repeated measurements of elevated blood pressure. Its risks, including damage to the kidney, heart, and brain, are directly proportional to blood pressure levels. Starting from 115/75 mm Hg, the risk of cardiovascular disease doubles with each increment of 20/10 mm Hg. The diagnosis relies on blood pressure measurements, not on patient symptoms, as hypertension is often asymptomatic until end-organ damage is imminent or...
3.8K